摘要
目的 :比较三组不同联合化疗方案对晚期非小细胞肺癌的疗效和毒性。方法 :统计分析用MIP(丝裂霉素、异环磷酰胺、顺铂 )MVP(丝裂霉、长春花碱酰胺、顺铂 )CAP(环磷酰胺、阿霉素、顺铂 )方案治疗的 87例晚期非小细胞肺癌病例的临床资料。结果 :MIP组有效率为 4 4 .8% (13/ 2 9) ,MVP 35.7% (10 / 2 8)CAP组有效率为 2 6 .7% (8/ 30 ) ,毒副反应为骨髓抑制及脱发。结论 :以长春花碱酰胺为主的MVP方案和以异环磷酰胺为主的MIP方案治疗晚期非小细胞肺癌是较为有效而安全的化疗方案。
Objective: To compare the efficacy and toxicity of three different chemotherapy protocols for advanced non-small-cell lung cancer(NSCLC).Methods:The clinical of 87 cases with advanced NSCLC treated with①mintomycin plus ifosfamide plus cisplatin (MIP,29 cases),②mitomycin C plus vindesine plus cisplatin (MVP,28 cases), and ③cyclophosphamide plus adriamycinplus cisplatin (CAP,30 cases) were analysed.Results:The response rate was 44.8% in patients treated with MIP, 35.7% in chose treated with MVP and 26.7% in chose with CAP, respectively. The major toxic reactions in the three groups were tocerable myelo-suppression and hair loss.Conclusion:MVP;and MIP are effective and safe chemotherapeutic protocols for the treatment of advanced NSCLC patients.
出处
《河北医学》
CAS
2001年第6期515-517,共3页
Hebei Medicine
关键词
非小细胞肺癌
药物疗法治疗
抗肿瘤药
化疗方案
Lung neoplasms
Drug therapy
Carcinoma non-small cell lung drug therapy
Antineoplastic agents combined
